Pirabbasi Elham, Zangeneh Mohammad Mahdi, Zangeneh Akram, Moradi Rohallah, Kalantar Mojtaba
Department of Nutrition Shoushtar Faculty of Medical Sciences Shoushtar Iran.
Biotechnology and Medicinal Plants Research Center Ilam University of Medical Sciences Ilam Iran.
Food Sci Nutr. 2024 Mar 28;12(5):3443-3451. doi: 10.1002/fsn3.4008. eCollection 2024 May.
The present research studied the cytotoxicity, antioxidant, and antidiabetic activities of biogenically synthesized silver nanoparticles (AgNPs) using () as a green mediator. Scanning electron microscopy (SEM), transmission electron microscopy (TEM), and ultraviolet-visible spectroscopy (UV-Vis) were employed to determine AgNPs. In the in vivo experiment, the model rats were categorized into different groups receiving 50, 100, 200, and 400 μg/kg of AgNPs and diabetic, positive, and normal groups ( = 10) using a random division. A single dose of streptozotocin (STZ) at 60 mg/kg was administered to induce diabetes and hepatotoxicity in rats. The administration of AgNPs was performed via intragastric administration for 25 days. On the final day, the levels of glucose and biochemical enzymes, namely aspartate aminotransferase (AST), alkaline phosphatase (ALP), alanine transaminase (ALT), and gamma-glutamyltransferase (GGT), were assessed in the serum. Following tissue processing, liver sections with a thickness of 5 μm were prepared. Later, the total volume of different liver components, such as hepatocytes, sinusoids, portal vein, central vein, hepatic arteries, and bile ducts, was measured. The portal vein and bile duct volumes did not vary significantly in groups treated by AgNPs. However, the volume of the central vein and hepatic arteries exhibited noticeable variations in groups treated by AgNPs. After administration of streptozotocin, the volume of hepatocytes and sinusoids increased significantly. However, treatment with a high dose of AgNPs significantly decreased the volume of hepatocytes and sinusoids. In diabetic rats, administering AgNPs reduced the fasting blood glucose levels compared to the model group. In addition, AgNPs decreased the elevated levels of AST and ALP enzymes in a manner that depended on the dosage of AgNPs used. This research demonstrates the hepatoprotective and antidiabetic properties of AgNPs, suggesting their potential implications as hepatoprotective and antidiabetic supplements to prevent diabetes.
本研究利用（）作为绿色介质，研究了生物合成银纳米颗粒（AgNPs）的细胞毒性、抗氧化和抗糖尿病活性。采用扫描电子显微镜（SEM）、透射电子显微镜（TEM）和紫外可见光谱（UV-Vis）对AgNPs进行表征。在体内实验中，将模型大鼠随机分为接受50、100、200和400μg/kg AgNPs的不同组以及糖尿病组、阳性对照组和正常组（每组n = 10）。以60mg/kg的单剂量链脲佐菌素（STZ）诱导大鼠糖尿病和肝毒性。通过胃内给药方式给予AgNPs，持续25天。在最后一天，评估血清中葡萄糖和生化酶（即天冬氨酸转氨酶（AST）、碱性磷酸酶（ALP）、丙氨酸转氨酶（ALT）和γ-谷氨酰转移酶（GGT））的水平。组织处理后，制备厚度为5μm的肝脏切片。随后，测量不同肝脏成分（如肝细胞、血窦、门静脉、中央静脉、肝动脉和胆管）的总体积。在接受AgNPs治疗的组中，门静脉和胆管体积没有显著变化。然而，在接受AgNPs治疗的组中，中央静脉和肝动脉的体积表现出明显变化。给予链脲佐菌素后，肝细胞和血窦的体积显著增加。然而，高剂量AgNPs治疗显著降低了肝细胞和血窦的体积。在糖尿病大鼠中，与模型组相比，给予AgNPs可降低空腹血糖水平。此外，AgNPs以依赖于所用AgNPs剂量的方式降低了AST和ALP酶的升高水平。本研究证明了AgNPs的肝保护和抗糖尿病特性，表明它们作为预防糖尿病的肝保护和抗糖尿病补充剂具有潜在意义。
